About Mondego Bio
Developing Breakthrough Cancer Immunotherapies - Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class Protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.
Facts about Mondego Bio
Facts about Mondego Bio
- Founding: 2025
- Focus : Manufacturer
- Industry : Pharma
Advertisement
